Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54) 📌Negative imaging, biopsy & cytology 🔹19% recurred; 13% developed distant recurrence 🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC 🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83% 🔹 20% required delayed RC or chemoRT 🔹 Baseline cT3–4 disease also associated with poorer outcomes 🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC. @urotoday #ESMO26

Outcomes of Patients with #MIBC Who Declined Radical Cystectomy in Perioperative Therapy Trials Conducted at San Raffaele Comprehensive Cancer Center. Presented by @CMercinelli @SanRaffaeleMI. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4Bxa9KE #BladderCancer #GUOnc @myESMO

Huge congrats @AndreaNecchi & team on this yet another novel trial. You are always pushing the envelope in bladder cancer! @CMercinelli @BrigidaMaiorano @giannatempopatr @UroDocAsh @montypal @PGrivasMDPhD @SpiessPhilippe @IBCG_BladderCA

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR Outcomes of pts with MIBC who decline RC in perioperative setting: Take-home message: 1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT 2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al. Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open esmoopen.com/article/S2059-7…

With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting. 33% CR rates vs 8% Nivo+placebo All pCR pts still event-free (median FUP 15.7m) Only 1 relapse event in major responders in N+V arm (pTa relapse) 4/5 pCR skipped RC in N+V arm. Safety was quite good. Pre-existing CD8+ infiltration associated with N+V Response. It was an illuminating academic-industry collaboration for me. Results simultaneously released today in @NatureMedicine @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR nature.com/articles/s41591-0…

Fantastic presentation by expert @AndreaNecchi ENERGIZE trial that did not meet its primary endpoint. Interesting ctDNA data;awaiting VOLGA trial at @myESMO #ESMOAmbassadors @OncoAlert @Uromigos @nataliagandur @DrKarineTawagi @shilpaonc @UroDocAsh @CMercinelli @BrigidaMaiorano

Defining clinical complete response after neoadjuvant therapy in #MIBC. @TomFlaigMD @CUAnschutz and @CMercinelli @SanRaffaeleMI join @pjhensley11 @UKYMedicine at #IBCG2026; Dr. Flaig calls #IMvigor011 a turning point for ctDNA. #WatchNow on UroToday > bit.ly/3W6G4RI #IBCG26 @IBCG_BladderCA @UroDocAsh

WATCH: Chiara Mercinelli, MD, (@CMercinelli) discusses a meta-analysis comparing neoadjuvant treatment strategies for cisplatin-eligible muscle-invasive bladder cancer. urologytimes.com/view/networ…

To mark Penile Cancer Awareness Day, the GSRGT is proud to officially launch PCARE — our new patient advocacy initiative supporting people affected by #PenileCancer. If you are a patient or caregiver looking for support or guidance, please contact us at pcare.gsrgt@gmail.com 📩 Special thanks to @SpiessPhilippe, @LuisMedinaMD, and @JadChahoud for bringing this initiative to life. @drgaganprakash @npaesa @CMercinelli @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @herneygarcia @PGrivasMDPhD @UroDocAsh @spsutkaMD @montypal @shilpaonc @orchidcancer @karima_oualla @VedangMurthy @UrogerliMD

🧬 Could PSMA PET/CT become more than a staging tool—and actually help us measure treatment response? Article 📰 sciencedirect.com/science/ar… PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review A systematic review of 11 studies evaluated PSMA PET/CT for treatment response assessment in hormone-sensitive #ProstateCancer . ➡️ ADT generally reduced PSMA expression, although an early flare was observed in a subset of lesions, particularly bone metastases. ➡️ Following radiotherapy ☢️ , PSMA reductions appeared greater when ADT was added. ✅ These findings suggest PSMA PET parameters could potentially help personalize treatment monitoring, but their association with long-term oncological outcomes remains to be established. @JennKa12, @MBauckneht, @ClaudiaKesch, @GGandaglia, @dr_rajwa, @Fabio_Zattoni, @AlbertoMartini_, @veerukasi, @Lara__Rodriguez, @fazekasMD, @TheGiesen, @m_martinamaggi, @CMercinelli, @miszczyk_marcin, @JGomezRivas, @ruimmbernardino, @alibourgi1_ali, @Tilki_De, @GMarra_MD, @EAU_YAUProstate @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

What do we gain by adding belzutifan to pembro in high-risk ccRCC post-nephrectomy? Our reconstructed IPD analysis of LITESPARK-022 pembro+belzu arm vs KN-564 placebo arm, now in @ESMOOpen, reveals a compelling survival signal: 🔹 DFS: HR 0.55 🔹 OS: HR 0.56 #RCC #GUOnc

Best part of the meeting is reaching out with friends and colleagues @IBCG_BladderCA @UroDocAsh @shilpaonc @giannatempopatr @PGrivasMDPhD @AndreaNecchi @apolo_andrea @CMercinelli @BrigidaMaiorano @AparnaKamatMD @NehaVapiwala

Wonderful dinner with amazing people at the 20th anniversary of @IBCG_BladderCA @UroDocAsh @PGrivasMDPhD @giannatempopatr @CMercinelli @spsutkaMD @carme_mir1 @BrigidaMaiorano

Already impressed with the truly global nature of #IBCG26 - and the meeting has not even officially started yet! Hats off to @UroDocAsh for bringing #bladdercancer experts around the 🌍 to discuss key topics from #NMIBC to #mUC. Was pleased to see @karima_oualla 🇲🇦, @giannatempopatr @CMercinelli @BrigidaMaiorano 🇮🇹, @drgaganprakash 🇮🇳 & so many others - anticipating great discussions today!

Let’s kick off #IBCG26 celebrating 20 years @IBCG_BladderCA @urotoday

Incredible to see the growth of @IBCG_BladderCA over 20y. At #IBCG26, @UroDocAsh highlights new members (incl @WesleyYipMD @AbhiTrip87 from @cityofhope), 🌎 site (28 countries!), publications (incl @EUplatinum highest rated article from @shilpaonc @UrogerliMD et al) & society collabs (@GTumorBoard @JSUO_official @TataMemorial @SIU_urology & more). Just brilliant!

Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin | @JCOOA_ASCO @ASCO @CMercinelli @Anto_cigliola @BrigidaMaiorano @vale_tateo @SanRaffaeleMI @MyUniSR @OncoAlert @urotoday ascopubs.org/doi/10.1200/OA-…

🚨 Is gemcitabine-cisplatin still the benchmark in MIBC? Article 📰 ascopubs.org/doi/10.1200/OA-… Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin A meta-analysis of three phase III trials in cisplatin 🧪eligible muscle-invasive #BladderCancer shows that intensified or immune-based neoadjuvant regimens outperform gemcitabine-cisplatin. ✅EVP produced the strongest improvements in event-free survival, overall survival, and pathologic complete response, while GC plus durvalumab and ddMVAC also improved outcomes. ➡️However, cross-trial differences and limited follow-up warrant caution. The findings underscore a rapidly evolving perioperative landscape and raise important questions about biomarkers 🎯 , overtreatment, toxicity, and bladder preservation. @CMercinelli @Anto_cigliola @BrigidaMaiorano @UroMoschini @F_Montorsi @Albert0Briganti @AndreaNecchi

Thank you to our growing global community for supporting the GSRGT and our mission! Interested in rare GU tumors? Follow @gtumors and join our growing global community! 🌎 @SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @UroOnc @SUO_YUO @CAU_URO @JadChahoud @benristau @PGrivasMDPhD @spsutkaMD @CMercinelli @LuisMedinaMD @herneygarcia @AndreaNecchi @apolo_andrea @VedangMurthy @ARRODRIGUEZMD @montypal @UrogerliMD @dramandeeparora @CurtisPettaway1 @karima_oualla

10 Must-Read Posts in GU Oncology This Week | First Week of August This week’s selection covers: • PSMAddition and ¹⁷⁷Lu-PSMA-617 in PSMA+ mHSPC • MR-guided adaptive SBRT to the prostate bed • Early enfortumab vedotin rash as a potential response marker • PSA nadir as a prognostic marker in mHSPC • Conditional survival in metastatic RCC after first-line nivo/ipi • Unmet needs in penile cancer • Neoadjuvant immunotherapy in MIBC: PURE-01, NureCombo, SURE2 • Nicheverse and spatial transcriptomics in ccRCC • Enzalutamide vs darolutamide doublet therapy in mHSPC • EORTC 2238 DE-ESCALATE in mHSPC @katy_beckermann @shilpaonc @fcounago @g_procopio_ @LuisMedinaMD @CMercinelli @nealshore @BertrandTOMBAL @ChrisWeeMD @AmandaNizamMD @jamecancerdoc @MosheOrnsteinMD 👉 oncodaily.com/genitourinary-… #GUOncology #OncoDaily